# CED Cannabis Science Digest: 3 Mental Health, Prenatal, and Oncology Caution Signals > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/2026-cannabis-prenatal-safety-signals-mental-health-oncology/ > **Published:** 2026-06-27T07:13:09-04:00 | **Last Modified / Clinically Audited:** 2026-09-27T22:05:09-04:00 > **Clinical Summary:** Explore 2026 cannabis prenatal safety signals highlighting mental health risks and oncology pilot findings for clinical caution and evidence framing. --- CED Clinical Relevance #58 Notable Clinical Interest Today did not produce a fresh nonduplicate cannabis science paper strong enough for a standalone full report, but it did produce three verified lower-certainty signals that sharpen psychiatric counseling, prenatal evidence framing, and oncology caution. Clinical Insight | CED Clinic The strongest standalone full-report candidates for June 27, 2026 were either exact duplicates of recent live CED Clinic coverage or too weak to justify a separate feature without overstating the evidence. The most defensible publication was a digest preserving three lower-certainty but clinically useful signals: a Europe-focused mental-health review linking high-potency cannabis and uneven health-system preparedness to underrecognized psychiatric burden, a broad placental pathophysiology review that clarifies why prenatal cannabis claims need careful evidence labeling, and a tiny randomized oncology pilot that generated biomarker hypotheses without demonstrating statistically significant benefit. None of these papers should be treated as treatment proof. Together, they improve how clinicians and careful readers talk about psychiatric risk, pregnancy evidence, and oncology uncertainty. DigestMental HealthPregnancyOncologyEvidence Limits Audience Patients, caregivers, cannabis clinicians, psychiatrists, pregnancy counselors, oncology clinicians, and evidence-focused medical readers Primary Topic Three verified cannabis caution signals on psychiatric risk context, prenatal placental evidence framing, and an underpowered oncology pilot trial Source [Read the full study](https://pubmed.ncbi.nlm.nih.gov/42358396/) Today’s cannabis science scan did not produce one fresh human clinical-trial-level paper strong enough for a standalone article, but it did surface three verified lower-certainty signals worth preserving: a Europe mental-health review focused on potency and health-system blind spots, a prenatal placental review that shows why pregnancy evidence needs careful translation, and a randomized oncology pilot whose biomarker trends were interesting but far from conclusive. What This Study Teaches Us This digest teaches a useful kind of restraint. Cannabis evidence can matter even when it does not prove efficacy. A psychiatric review can sharpen counseling about potency and screening. A prenatal review can explain why placental and exposure-model details matter before claims are generalized. A randomized oncology pilot can generate hypotheses without justifying a treatment headline. Readers need those distinctions if cannabis science is going to stay clinically honest. Why This Matters Mental-health risk, pregnancy counseling, and cancer-supportive-care conversations are three of the most emotionally charged areas in [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/). These papers matter because they narrow the claim in each lane. The psychiatric review supports closer attention to potency and underdetected burden. The prenatal review shows that placental biology and exposure reconstruction matter, but that broad multi-substance methods papers cannot be read as direct cannabis-outcomes proof. The oncology pilot reminds readers that a blinded trial can still be too small and exploratory to justify broad clinical conclusions. Study Snapshot Post Type Evidence digest using the canonical CED layout Batch ID 11d49a9e32892081 Items Reviewed 3 verified, nonduplicate, digest-eligible items Editorial Decision Useful verified lower-certainty signals preserved after duplicate-blocked and sub-threshold full-report candidates made a standalone post genuinely impossible Item 1 Europe mental-health consequences review Item 2 Prenatal placental pathophysiology review Item 3 Randomized breast-cancer chemotherapy cannabis-oil pilot Primary Dates June 10, 2026; June 22, 2026; June 17, 2026 Content Lanes Evidence Check; Safety Signal; Clinical Evidence Update Digest Standard Signals preserved with treatment-proof language explicitly avoided Related Reading 3 verified live CED Clinic internal links Clinical Bottom Line These papers are most useful for framing conversations, not settling them. The Europe review supports stronger psychiatric screening and potency awareness. The prenatal review supports more precise evidence labeling. The oncology pilot supports more research, not a treatment recommendation. Digest Contents - [Digest Card 1 | Europe Mental Health Risk Context](#digest-card-2-digest-card-1-europe-mental-health-risk-context) - [Digest Card 2 | Prenatal Placental Evidence Framing](#digest-card-3-digest-card-2-prenatal-placental-evidence-framing) - [Digest Card 3 | Oncology Biomarker Pilot](#digest-card-4-digest-card-3-oncology-biomarker-pilot) Why These Three Papers Belong Together These papers address different clinical conversations, but they all matter for the same reason: they make it harder to overclaim what cannabis evidence currently proves. The Europe review is strongest as risk-context and system-readiness framing. The placental review is strongest as a caution against flattening pregnancy evidence into one-direction certainty. The oncology pilot is strongest as a reminder that a randomized design still needs enough size and signal to support a meaningful clinical conclusion. Digest Card 1 | Europe Mental Health Risk Context **Title:** Mental health consequences of contemporary [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) in Europe: potency, patterns of use, and health system context. **Authors / source / date / lane:** Justyna Sniadach, Sylwia Szymkowiak, Przemyslaw Osip, Wiktor Orlof, and Napoleon Waszkiewicz; *Frontiers in Psychiatry*; June 10, 2026. PMID 42358396. DOI 10.3389/fpsyt.2026.1778831. Content lane: Evidence Check. Source URL: https://pubmed.ncbi.nlm.nih.gov/42358396/ **What was investigated:** This narrative review examined peer-reviewed literature, epidemiologic reports, and national health data from 2015 through 2025 to assess how contemporary [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/), product potency, and health-system preparedness interact across Europe. **What it appeared to find:** The review linked stronger THC products and changing use patterns to higher risks of psychosis, anxiety, panic symptoms, derealisation episodes, and [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/), while arguing that monitoring and clinical preparedness are much more robust in some Western European settings than in Central and Eastern Europe. **Limitations and uncertainty:** This is a narrative review, not a new prospective cohort or trial, and Europe-wide comparisons depend on uneven surveillance systems, reporting practices, and diagnostic infrastructure. It cannot quantify one patient’s risk from one product or pattern of use. **Why it is noteworthy:** Patients and clinicians often discuss cannabis potency as if the risk picture were already obvious and uniform. This paper is useful because it shows how product strength, patterns of use, stigma, and health-system blind spots can distort what actually gets detected and treated. Digest Card 2 | Prenatal Placental Evidence Framing **Title:** Placental Pathophysiology in Maternal Psychoactive Substance Use: Biological, Clinical, and Forensic Perspectives. **Authors / source / date / lane:** Oscar Fraile-Martinez, Natalia Rubio-Bedoya, Cielo Garcia-Montero, Diego Liviu Boaru, Patricia de Castro-Martinez, Julia Bujan, Laura Lopez-Gonzalez, Raul Diaz-Pedrero, Natalio Garcia-Honduvilla, Melchor Alvarez-Mon, Miguel A. Saez, Juan A. De Leon-Luis, Coral Bravo, and Miguel A. Ortega; *Cells*; June 22, 2026. PMID 42346155. DOI 10.3390/cells15121128. Content lane: Safety Signal. Source URL: https://pubmed.ncbi.nlm.nih.gov/42346155/ **What was investigated:** This review synthesized how psychoactive substances, including cannabis, alcohol, tobacco, cocaine, opioids, and synthetic drugs, can affect placental vascularization, oxidative balance, epigenetic regulation, cellular viability, and exposure reconstruction. **What it appeared to find:** The authors argued that placental tissue can provide objective clues about prenatal substance exposure and that placental disruption may contribute to impaired nutrient and oxygen transfer, growth restriction, preterm birth, congenital anomalies, and later neurodevelopmental risk. **Limitations and uncertainty:** The paper is not a cannabis-only pregnancy outcomes study. It is broader than cannabis, spans multiple substances and evidence types, and cannot by itself tell readers what a specific cannabis product or exposure dose does in human pregnancy. **Why it is noteworthy:** Pregnancy cannabis claims are often oversimplified. This paper is worth digest treatment because it clarifies why placental biology, exposure reconstruction, and mixed-substance context matter when readers interpret prenatal cannabis headlines. Digest Card 3 | Oncology Biomarker Pilot **Title:** Cannabis Oil and Exploratory Gut-Immune Signatures During Breast Cancer Chemotherapy: A Randomized Pilot Trial. **Authors / source / date / lane:** May Soe Thu, Thunnicha Ondee, Barry J. Campbell, Joanne L. Fothergill, Mawin Vongsaisuwon, Chanida Vinayanuwattikun, Kamonwan Banchuen, Sunchai Payungporn, Phanupong Phutrakool, Preecha Nootim, Pajaree Chariyavilaskul, Kulthanit Wanaratna, Krit Pongpirul, and Nattiya Hirankarn; *Biomedicines*; June 17, 2026. PMID 42351795. DOI 10.3390/biomedicines14061367. Content lane: Clinical Evidence Update. Source URL: https://pubmed.ncbi.nlm.nih.gov/42351795/ **What was investigated:** In a double-blind placebo-controlled pilot, 10 women receiving breast-cancer chemotherapy were randomized to cannabis oil or placebo for 12 weeks while researchers tracked exploratory fecal short-chain fatty acids and plasma cytokines. **What it appeared to find:** The cannabis group showed directional numerical trends toward lower proteolytic dysbiosis markers and lower inflammatory cytokines, but none of the exploratory endpoints reached statistical significance. **Limitations and uncertainty:** This was an extremely small pilot with only 10 participants, exploratory biomarker endpoints, and no statistically significant efficacy result. It cannot support a claim that cannabis oil improves oncology outcomes, symptoms, or immune status in routine care. **Why it is noteworthy:** Randomized oncology cannabis trials are still relatively rare. This study is useful because it shows how early signals can justify better-designed follow-up work while still falling far short of a publishable standalone treatment claim. How Strong Is This Evidence? All three items are primary-source verified and clinically relevant, but they sit at very different evidence ceilings. The Europe paper is a narrative review that is useful for risk framing, not causal quantification. The placental paper is a broad mixed-substance review that helps interpret prenatal evidence without isolating cannabis-specific outcomes. The oncology paper is randomized, which matters, but the sample is too small and the endpoints too exploratory to support confident efficacy language. Where This Paper Deserves Skepticism A skeptical reader should keep the evidence labels attached. High-potency risk context is not the same as a prospective causal cohort. Placental pathophysiology is not the same as a cannabis-only pregnancy outcome trial. A randomized oncology pilot is not the same as a definitive symptom or survival study. The value of the digest is precision, not certainty. What This Paper Does Not Show This digest does not show that every high-potency cannabis product causes psychiatric illness, that placental pathology papers can directly quantify cannabis-specific pregnancy outcomes, or that cannabis oil improves inflammatory status or clinical outcomes during breast-cancer chemotherapy. It also does not justify turning any of these papers into treatment proof. How This Fits With the Broader Clinical Conversation Cannabis evidence often travels fastest in precisely the areas where readers most want certainty: mental health, pregnancy, and cancer. Those are also the areas where overstatement can do the most harm. The Europe review is best used to sharpen screening and potency counseling. The placental review is best used to explain why prenatal evidence is harder to simplify than headlines suggest. The oncology pilot is best used to justify better trials, not new recommendations. That does not make these papers weak. It makes them useful in the correct lane: evidence framing, counseling caution, and research-direction clarity. Dr. Caplan’s Take *The psychiatry review is useful because it reminds readers that product potency and clinical detection are part of the same story. If a health system misses cannabis-related psychiatric burden, the public conversation can look cleaner than the clinical reality.* *The placental review matters because pregnancy counseling needs evidence labels, not vague certainty. When a paper spans multiple substances and multiple biological mechanisms, the responsible move is to narrow the claim, not stretch it.* *The oncology pilot is the kind of paper I want readers to handle carefully. A blinded design is better than anecdote, but a tiny hypothesis-generating biomarker study is still not a clinical green light.* What a Careful Reader Should Take Away A careful reader should come away with sharper questions, not stronger promises. These papers help define where psychiatric, prenatal, and oncology cannabis conversations still need more discipline than confidence. Evidence Interpretation Guide Table of Contents - [How to Read Mixed-Lane Cannabis Signals Without Letting Any One of Them Overclaim](#How_to_Read_Mixed-Lane_Cannabis_Signals_Without_Letting_Any_One_of_Them_Overclaim)[A Better Reading Order for This Digest](#A_Better_Reading_Order_for_This_Digest) - [The Same Study Can Mean Different Things Depending on the Question Being Asked](#The_Same_Study_Can_Mean_Different_Things_Depending_on_the_Question_Being_Asked)[Useful Caution Is Still Useful](#Useful_Caution_Is_Still_Useful) - [Counseling Precision Is the Main Gain](#Counseling_Precision_Is_the_Main_Gain) - [Potency and Detection Belong in the Same Discussion](#Potency_and_Detection_Belong_in_the_Same_Discussion) - [Placental Biology Helps, but It Does Not Finish the Pregnancy Question](#Placental_Biology_Helps_but_It_Does_Not_Finish_the_Pregnancy_Question) - [A Randomized Pilot Can Still Be Far Too Early](#A_Randomized_Pilot_Can_Still_Be_Far_Too_Early) - [The Good Form of Skepticism Is Specific](#The_Good_Form_of_Skepticism_Is_Specific) - [Public Messaging Needs Better Evidence Categories](#Public_Messaging_Needs_Better_Evidence_Categories) - [What Better Follow-Up Would Look Like](#What_Better_Follow-Up_Would_Look_Like) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) ## How to Read Mixed-Lane Cannabis Signals Without Letting Any One of Them Overclaim A useful cannabis digest does not pretend that every paper answers the same type of question. One paper may help with public-health framing, another with prenatal evidence interpretation, and another with trial design skepticism. The right reading strategy is to ask what each study design can actually support before borrowing its language for counseling, risk communication, or treatment expectations. ### A Better Reading Order for This Digest **Start with the evidence lane**Ask whether the paper is a review, a broad mixed-substance synthesis, or a randomized pilot. That tells you how close it is to direct patient guidance. **Separate counseling value from treatment proof**A paper can be very useful for psychiatric screening, prenatal caution, or oncology trial design even when it does not prove efficacy or quantify risk precisely. **Watch for hidden scope shifts**A Europe-wide mental-health review, a multi-substance placental paper, and a tiny oncology pilot all become misleading if they are summarized as if they answered a single yes-or-no cannabis question. **Keep the claim inside the study ceiling**If the study cannot establish causality, cannabis-only pregnancy outcomes, or meaningful clinical benefit, the summary should not imply that it does. Clinical Framing Question Which of these studies actually changes a clinician’s next counseling conversation today, and which ones mainly improve how that clinician should judge future claims? Patient-Friendly Question Do these papers prove cannabis helps or harms in a simple way, or do they mostly show why mental-health, pregnancy, and oncology cannabis claims still need careful limits? The Bottom Line These studies improve evidence literacy more than they establish new rules of care. That is still valuable, but only when the evidence labels stay visible. CED Perspective Lens ## The Same Study Can Mean Different Things Depending on the Question Being Asked Scientific papers rarely answer a single question. Patients, clinicians, researchers, and critics can read the same data differently. These evidence-based lenses show where this trial is useful, where it remains uncertain, and how easily it can be overstated. Overview The same digest lands differently for a psychiatrist worried about potency-linked risk, a pregnancy counselor interpreting mixed prenatal evidence, and an oncology reader looking for stronger cannabis data during chemotherapy. These eight panels keep those differences explicit. #### Useful Caution Is Still Useful Not every important cannabis paper proves a treatment point. Some improve how a patient should interpret risk, uncertainty, and what is still unknown. This digest is useful because it shows three different ways evidence can matter without being ready to settle a clinical question. Lens takeaway A careful paper can still be worth reading even when it narrows a claim instead of expanding it. #### Counseling Precision Is the Main Gain The Europe review sharpens potency and psychiatric-screening conversations. The placental review sharpens evidence labeling in pregnancy discussions. The oncology pilot sharpens how cautiously biomarker findings should be explained. That is a meaningful clinical gain even without a new prescribing signal. Lens takeaway The practical output is better framing, not a new broad recommendation. #### Potency and Detection Belong in the Same Discussion The Europe review is strongest when it is used to connect product potency with the health-system question of who actually gets screened, diagnosed, and counted. A psychiatric burden can be real while still being unevenly detected, which matters for both patients and systems. Lens takeaway Potency risk is partly a clinical-detection problem, not just a product problem. #### Placental Biology Helps, but It Does Not Finish the Pregnancy Question The placental review reminds readers that prenatal substance evidence often lives in biological mechanisms, mixed exposures, and indirect markers before it reaches clean human outcomes. That makes careful counseling more important, not less. Lens takeaway Pregnancy counseling should be cautious, specific, and clear about evidence type. #### A Randomized Pilot Can Still Be Far Too Early Randomization improves credibility, but a tiny biomarker pilot without significant findings cannot support a confident clinical oncology message. The right lesson is that oncology [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) needs better-powered follow-up, not stronger promotional language. Lens takeaway A better design is helpful, but sample size and endpoint strength still determine the claim. #### The Good Form of Skepticism Is Specific A skeptical reader should not flatten these three papers into equally strong or equally weak. Each one has a different kind of utility and a different ceiling. The discipline is to keep each paper inside the claim it actually earned. Lens takeaway Specific skepticism preserves nuance better than blanket dismissal. #### Public Messaging Needs Better Evidence Categories Mental-health, pregnancy, and cancer messaging are all vulnerable to distortion when reviews, mechanistic work, and small pilots are spoken about as if they were interchangeable. These papers argue for clearer public-facing evidence labels around [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) and risk. Lens takeaway Evidence categories should stay visible in public cannabis discussions. #### What Better Follow-Up Would Look Like The Europe review points toward better surveillance and diagnostic harmonization. The placental review points toward cleaner cannabis-specific prenatal models and outcome bridges. The oncology pilot points toward larger trials with clinically meaningful endpoints, not just exploratory biomarkers. Those next steps matter because they raise the evidence ceiling where current confidence is limited. Lens takeaway Better follow-up means sharper methods and endpoints, not stronger rhetoric. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=CED+Cannabis+Science+Digest%3A+3+Mental+Health%2C+Prenatal%2C+and+Oncology+Caution+Signals&url=https%3A%2F%2Fcedclinic.com%2Fcannabis-science-digest-june-27-2026-mental-health-prenatal-oncology-signals%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcannabis-science-digest-june-27-2026-mental-health-prenatal-oncology-signals%2F) [BlueSky](https://bsky.app/intent/compose?text=CED+Cannabis+Science+Digest%3A+3+Mental+Health%2C+Prenatal%2C+and+Oncology+Caution+Signals%20https%3A%2F%2Fcedclinic.com%2Fcannabis-science-digest-june-27-2026-mental-health-prenatal-oncology-signals%2F) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source: [Open the Europe mental-health review on PubMed.](https://pubmed.ncbi.nlm.nih.gov/42358396/) Related Reading at CED Clinic Continue exploring the evidence [Cannabis Use in Early-Onset Psychosis: What the New Meta-Analysis Shows](https://cedclinic.com/early-onset-psychosis-cannabis-meta-analysis/) Useful mental-health companion reading because it shows how one fresh psychosis-focused meta-analysis can complement the broader Europe psychiatric-risk framing in this digest. [Read the psychosis context](https://cedclinic.com/early-onset-psychosis-cannabis-meta-analysis/) [Prenatal Cannabis Exposure and Brain Development: What a New Neuroimaging Study Adds](https://cedclinic.com/prenatal-cannabis-exposure-brain-development-neuroimaging-study/) Helpful prenatal context because it links pregnancy cannabis questions to developmental outcomes while this digest explains why placental and exposure-model evidence needs careful interpretation. [Read the prenatal context](https://cedclinic.com/prenatal-cannabis-exposure-brain-development-neuroimaging-study/) [Cannabis in Oncology Nursing: Reducing Polypharmacy and Managing Symptoms](https://cedclinic.com/cannabis-in-oncology-nursing-reducing-polypharmacy-and-managing-symptoms/) Useful oncology companion reading because it keeps symptom-management conversations grounded in [patient care](https://cedclinic.com/cannabis-cardiovascular-risk-impact/) while this digest shows how far a tiny exploratory biomarker trial still is from practice-changing evidence. [Read the oncology context](https://cedclinic.com/cannabis-in-oncology-nursing-reducing-polypharmacy-and-managing-symptoms/) ## Frequently Asked Questions What ties these three papers together? They each improve cannabis counseling by narrowing a claim rather than expanding it. One paper sharpens psychiatric-risk context, one sharpens prenatal evidence framing, and one sharpens how cautiously to read a tiny oncology pilot. Does the Europe review prove that high-potency cannabis always causes psychosis or anxiety? No. It is a narrative review that links stronger THC products and changing use patterns to greater psychiatric concern, but it does not calculate one person’s exact risk or prove the same effect in every setting. What is the main practical lesson from the Europe review? Potency matters, but so do detection systems. If screening, diagnosis, and reporting are inconsistent, the real psychiatric burden can be underestimated. Does the placental review isolate cannabis-specific pregnancy outcomes? No. It covers multiple psychoactive substances and focuses on placental biology, clinical interpretation, and forensic context. It is useful for framing, not for isolating one cannabis exposure effect. Why include a broad multi-substance placental review in a cannabis digest? Because pregnancy cannabis claims are often interpreted through placental and exposure evidence. This paper helps readers understand why that evidence is complicated and why evidence labels matter. Does the oncology pilot show that cannabis oil helps women receiving chemotherapy? No. The trial reported only directional biomarker trends and none of the exploratory endpoints reached statistical significance. What were the biggest limits of the oncology pilot? The sample was extremely small at 10 participants, the endpoints were exploratory biomarkers rather than strong clinical outcomes, and the findings were hypothesis-generating rather than confirmatory. Are any of these three papers treatment proof? No. The Europe paper is a review, the placental paper is a broad mixed-substance synthesis, and the oncology paper is a very small pilot trial. How should clinicians use a digest like this? As a way to improve counseling precision. These papers are most useful for risk framing, evidence labeling, and explaining uncertainty honestly. What would raise confidence beyond what this digest can support? Better surveillance and harmonized psychiatric monitoring, cleaner cannabis-specific prenatal outcome research, and larger oncology trials with clinically meaningful endpoints would all raise the evidence ceiling. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).